for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

グレンマーク・ファーマシューティカルズ

GLEN.NS

現在値

640.40INR

変化

0.90(+0.14%)

出来高

1,921,799

本日のレンジ

626.00

 - 

647.15

52週レンジ

398.00

 - 

658.20

∙ 約20分前の相場を表示しています。

適時開示

Glenmark Pharma Launches Tiogiva In The UK

June 15 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::LAUNCHES BIOEQUIVALENT VERSION OF TIOTROPIUM BROMIDE DRY POWDER INHALER UNDER BRAND NAME TIOGIVA IN THE UK.Further company coverage: GLEN.NS. ((Reuters.Briefs@thomsonreuters.com;)).

Glenmark Pharmaceuticals Gets ANDA Approval For Icatibant Injection

May 24 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GLENMARK PHARMACEUTICALS LTD - RECEIVES ANDA APPROVAL FOR ICATIBANT INJECTION, 30 MG/3 ML (10 MG/ML) SINGLE-DOSE PREFILLED SYRINGE.

Glenmark Pharma Launches Ryaltris-AZ Nasal Spray In India

May 3 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::LAUNCHES RYALTRIS-AZ NASAL SPRAY FOR TREATMENT OF MODERATE TO SEVERE ALLERGIC RHINITIS, IN INDIA.LAUNCHES RYALTRIS-AZ AT 175 RUPEES PER PACK OF 75 METERED DOSES.

Glenmark Pharmaceuticals Says Unit To Commercialize Ryaltris Nasal Spray In Canada

March 22 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GLENMARK PHARMACEUTICALS - UNIT TO COMMERCIALIZE RYALTRIS NASAL SPRAY IN CANADA.

Celon Pharma Signs License Deal With Glenmark Pharmaceuticals Regarding Salmex

March 3 (Reuters) - Celon Pharma Sa <CLNP.WA>::SAID ON TUESDAY IT HAS SIGNED LICENSE DEAL WITH INDIA-BASED GLENMARK PHARMACEUTICALS REGARDING COOPERATION ON REGISTRATION, SALE AND DISTRIBUTION OF A PRODUCT, KNOWN IN POLAND AS SALMEX, IN COUNTRIES MAINLY IN MIDDLE EAST, SOUTH AMERICA AND ASIA.THE PRODUCT IS A COMBINATION OF FLUTICASONE AND SALMETEROL IN A DRY POWDER INHALER.DEAL HAS BEEN SIGNED FOR A PERIOD OF 10 YEARS.UNDER DEAL GLENMARK HAS AN EXCLUSIVE RIGHT TO SELL THE PRODUCT ON THE MARKETS LISTED IN THE CONTRACT, WHILE CELON PHARMA HAS AN EXCLUSIVE RIGHT TO MANUFACTURE THE PRODUCT FOR SALE.

Glenmark Pharma Gets Russian Marketing Approval For Ryaltris Nasal Spray

Feb 22 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::SWISS UNIT GOT MARKETING APPROVAL FROM MINISTRY OF HEALTH OF RUSSIAN FEDERATION FOR ITS RYALTRIS NASAL SPRAY.RYALTRIS EXPECTED TO BE MADE AVAILABLE TO PATIENTS IN RUSSIA IN Q1 FY 2021-22.

Glenmark Receives ANDA Approval for Clindamycin Phosphate Gel

Feb 11 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::RECEIVES ANDA APPROVAL FOR CLINDAMYCIN PHOSPHATE GEL USP, 1%.

Glenmark Pharmaceuticals Gets ANDA Approval For Amphetamine Sulfate Tablets

Jan 28 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::RECEIVES ANDA APPROVAL FOR AMPHETAMINE SULFATE TABLETS USP, 5 MG AND 10 MG.

Glenmark Pharma Gets Tentative U.S. FDA Approval For Axitinib Tablets

Dec 1 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::GOT TENTATIVE APPROVAL BY U.S. FDA FOR AXITINIB TABLETS, 1 MG AND 5 MG.

Glenmark Pharma Announces Results Of Umifenovir & Favipiravir Combination Trial For Treating Moderate COVID-19

Oct 9 (Reuters) - Glenmark Pharmaceuticals Ltd <GLEN.NS>::ANNOUNCED RESULTS OF COMBINATION TRIAL WITH UMIFENOVIR & FAVIPIRAVIR FOR TREATMENT OF MODERATE HOSPITALIZED COVID-19 PATIENTS.STUDY SHOWED NO SUPERIOR CLINICAL OUTCOMES WITH ADDITION OF UMIFENOVIR.MEDIAN TIME TO CLINICAL CURE IMPROVED BY ONLY 1 DAY IN PATIENTS WHO RECEIVED COMBINATION, WHICH WAS NOT STATISTICALLY SIGNIFICANT.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up